Drugs / Tiprogrel
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06584812 | Sep → Dec 2024 | acute coronary syndrome, ischemic stroke | Tianjin Institute of Pharmaceutical Research Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06601127 | Feb 2025 → Apr 2026 overdue | ischemic stroke | Tianjin Institute of Pharmaceutical Research Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tiprogrel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06601127 ↗ |
| Action | Inhibit | “P2Y12 receptor antagonist” NCT06584812 ↗ |
| Route | Oral | “Tiprogrel is a novel oral P2Y12 receptor antagonist.” NCT06584812 ↗ |